PROVIDENCE – Biotechnology company EpiVax Inc. celebrated its 19th year in business this month with an updated logo and a tease of “other surprises” to be announced soon.
Katie Porter, a business-development and sales associate at the firm, wrote a May 18 post on the EpiVax website to commemorate the anniversary of EpiVax’s incorporation in 1998 and highlight the company’s recent achievements, including its recognition as one of the Providence Business News 2017 Best Places to Work and the announcement of its first commercial license for the Tregitope immune-modulating technology.
Safety Is a Growth Strategy for Rhode Island Manufacturing
For manufacturers, safety is often discussed in the language of compliance: inspections, recordkeeping, required training,…
Learn More
“In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and worldwide, and our in-silico user base is extensive,” wrote Porter. “We are seen as the go-to company for immunogenicity screening, we are considered founding members of the ‘gene-to-vaccine’ movement towards epitope-driven vaccines … There are other surprises in store for EpiVax, which will be announced soon, so stay tuned!”
Porter also unveiled the “latest evolution” of EpiVax’s logo, a sleeker and more modern design that dropped the “Inc.” from the EpiVax name and swapped the old logo’s 3-D stylization for a minimalist look while retaining its signature blue and purple color scheme.
On May 24, EpiVax CEO Dr. Anne S. De Groot announced a newly published study conducted with EpiVax’s immunoinformatics tool JanusMatrix to identify amino acids that might explain why vaccines for the H7N9 influenza are less effective than vaccines for other types of the flu.
De Groot said the study represented a new approach to screening and selecting vaccine strains using immunoinformatics tools and a “humanized” mouse, in other words, a mouse engrafted with human genes or cells.
Kaylen Auer is a PBN contributing writer.
